The following policies were recently reviewed for annual update. The full texts of these policies are available in the Provider section of bcbsri.com:
- Bioimpedance Devices for Detection and Management of Lymphedema
- Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover
- Breast Pump - Hospital Grade
- Drug Testing
- Electrical Stimulation and Electromagnetic Therapy for Wound Treatment
- Glucose Monitoring - Continuous
- Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease
- Human Leukocyte Antigen (HLA) Testing Mandate
- Hyperbaric Oxygen Therapy
- Immune Cell Function Assay
- Intracellular Micronutrient Analysis
- Laser Treatment of Onychomycosis
- Measurement of Serum Antibodies to Selected Biologic Agents
- Measurement of Small Low-Density Lipoprotein (LDL) Particles
- Medical Necessity
- Multimarker Serum Testing Related to Ovarian Cancer
- New Technology and Miscellaneous Services
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
- Pulsed Radiofrequency for the Treatment of Chronic Pain
- Radiofrequency Coblation Tenotomy for Musculoskeletal Conditions
- Serum Biomarker Human Epididymis Protein 4
- Transcutaneous Electrical Nerve Stimulation
- Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance
- Vitamin-D Testing
We also post monthly drafts of medical policies being created or reassessed for your review. As a reminder, you can provide comments on draft policies for up to 30 days. Draft policies are located on the Provider homepage, under the Medical Policies section, under the drop-down “Draft Medical Policies.”